RE:Paladin startup.The current environnement is now very different. I do own GUD and RX.v but we can expect some issues about pricing over next years. Median OECD prices for patented drugs are probably still below +/- 22 % below those in Canada and maybe some changes are coming on that front.
https://business.financialpost.com/news/withdrawal-symptoms-could-lower-drug-prices-hurt-more-than-just-big-pharma
Modernizing the Schedule
The proposed amendments to the Regulations would reconstitute the Schedule with countries that are more aligned with Canada economically and from a consumer protection standpoint. The number of countries would also be increased to make the benchmarking process less sensitive to missing or skewed price data from individual countries, but not to the point of imposing undue regulatory burden on patentees.
Proposal #2: It is proposed that the countries in the Schedule to the Regulations be revised as follows: | Current Schedule | Proposed New Schedule |
| * New countries added to the list |
- France
- Germany
- Italy
- Sweden
- Switzerland
- United Kingdom
- United States
| - Australia*
- Belgium*
- France
- Germany
- Italy
- Japan*
- Netherlands*
- Norway*
- South Korea*
- Spain*
- Sweden
- United Kingdom
|
https://www.canada.ca/en/health-canada/programs/consultation-regulations-patented-medicine/document.html#a2